ROIV
Roivant Sciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ROIV
Roivant Sciences Ltd.
A healthcare company that focused on applying technology to drug development
7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom
--
Roivant Sciences Ltd., a company registered in Bermuda, was established on July 6, 2020. Roivant's mission is to improve healthcare delivery to patients by treating every inefficiency as an opportunity. Roivant utilizes the Roivant platform to launch "Vants" — flexible and focused biopharmaceutical and health technology companies to develop transformative drugs faster by building technology and cultivating talent in a creative way.
Earnings Call
Q4/2024
Estimate EPS-0.31
Actual EPS-0.19
Estimate Revenue32.61M
Actual Revenue28.93M
Roivant Sciences' Q4 2024: Unpacking Key Contradictions in DM Study and Pricing Strategy
May 29,2025 02:27
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS-0.26
Actual EPS0.12
Estimate Revenue31.50M
Actual Revenue55.13M
Roivant's Q1 2025 Earnings Call: Unraveling the Contradictions in Brepo's DM Market Positioning and Efficacy Expectations
Aug 11,2025 12:35
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ROIV has released its 2026 Q2 earnings. EPS was reported at -0.17, versus the expected -0.3, beating expectations. The chart below visualizes how ROIV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ROIV has released its 2026 Q2 earnings report, with revenue of 1.57M, reflecting a YoY change of -64.89%, and net profit of -166.04M, showing a YoY change of 40.68%. The Sankey diagram below clearly presents ROIV's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
